Current Medical Mycology最新文献

{"title":"A case of prosthetic joint infection due to the rare opportunist yeast, <i>Cyberlindnera fabianii</i>.","authors":"Nurhafiza Ishak, Kallaivani Pachayappan, Chu Lee Hwa, Muhammad Asyraf Mohamad Kamil","doi":"10.22034/CMM.2023.345063.1418","DOIUrl":"10.22034/CMM.2023.345063.1418","url":null,"abstract":"<p><strong>Background and purpose: </strong>Invasive fungal infections caused by <i>Cyberlindnera fabianii</i> (<i>Cy. fabianii</i>) have recently increased despite the low virulence potential of this yeast. However, limited information about the widely-used commercial biochemical identification systems has led to an underestimation of <i>Cy. fabianii</i> infections in clinical settings.</p><p><strong>Case report: </strong>This study reports a case of prosthetic joint infection in a patient who had a previous history of total knee replacement surgery. <i>Cy. fabianii</i> was recovered from intraoperative culture specimens identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and confirmed using molecular assays. It was, however, initially misidentified as <i>Candida utilis</i> by phenotypic identification.</p><p><strong>Conclusion: </strong>Due to the emergence of uncommon yeast species, it is important to accurately identify and perform antifungal susceptibility testing on uncommon yeast isolates for appropriate management.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 3","pages":"45-49"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, predictors, and outcome of pulmonary mucormycosis in COVID-19 associated rhino orbital mucormycosis in a tertiary care center in South India.","authors":"Karthigeyan Thanjavur Sethuraman, Jayaraj Athimanjeri Thiruvengadam, Abinaya Ravichandran, Santhi Thoppappatty Sengottaiyan","doi":"10.22034/cmm.2023.345154.1486","DOIUrl":"10.22034/cmm.2023.345154.1486","url":null,"abstract":"<p><strong>Background and purpose: </strong>India witnessed an explosive rise in mucormycosis following COVID-19 infection. Pulmonary mucormycosis closely followed rhino orbital mucormycosis as the most common presentation. The need for advanced resources and lack of clinical suspicion for COVID-19-associated pulmonary mucormycosis led to widespread underdiagnosis and poor response to late therapy. The present study aimed to assess the prevalence of pulmonary mucormycosis in COVID-19-associated rhino-orbital mucormycosis using non-invasive techniques, such as sputum microscopy and chest imaging.</p><p><strong>Materials and methods: </strong>A prospective observational study was conducted at the Institute of Internal Medicine, Rajiv Gandhi Government General Hospital in Chennai, India between June 2021 and July 2021. All hospitalized patients with proven rhino orbital mucormycosis with or without cerebral involvement within three months of confirmed COVID-19 infection who had clinical symptoms compatible with pulmonary mucormycosis were included in this study. These patients were screened for probable and possible COVID-19-associated pulmonary mucormycosis using computed tomography (CT) chest imaging and sputum microscopy within 48 h of hospital admission.</p><p><strong>Results: </strong>Based on the findings, 8 (16%) out of 50 patients with rhino-orbital mucormycosis, had associated possible or probable pulmonary mucormycosis. All 8 patients were diabetics and had characteristic CT chest findings while only half of them had positive sputum microscopy. A higher prevalence of probably disseminated COVID-19-associated mucormycosis was noted among 51-60-year-old males with the use of corticosteroids and oxygen for COVID-19 therapy. The mortality rate was 100% in probably disseminated mucormycosis, 50% in possible disseminated mucormycosis, and only 9.5% in isolated rhino-orbital mucormycosis.</p><p><strong>Conclusion: </strong>Non-invasive and feasible methods, such as sputum microscopy and chest imaging can be considered for early screening and intensive management of probably disseminated mucormycosis to improve prognosis.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 3","pages":"33-37"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the effects of itraconazole and prednisolone on <i>fibroblast growth factor</i>-2 gene expression and clinical manifestations in patients with persistent severe asthma.","authors":"Mahsa Manafi Varkiani, Majid Mirsadraee, Zahra Anhaee Nasseri, Mohammadreza Khakzad, Shadi Ghaffari, Tayebeh Rabbani Nia","doi":"10.22034/CMM.2023.345036.1401","DOIUrl":"10.22034/CMM.2023.345036.1401","url":null,"abstract":"<p><strong>Background and purpose: </strong>Considering the possible role of fungal sensitization in the treatment of resistant asthma, which may lead to the remodeling of bronchial structure, we theorized that itraconazole could result in better control of asthma. In this regard, this study aimed to compare the effects of itraconazole and prednisolone (routinely prescribed) on clinical, structural, and biomarker findings of the remodeling of asthma.</p><p><strong>Materials and methods: </strong>This double-blind controlled randomized clinical trial was performed on 70 adult patients suffering from severe persistent asthma. The intervention group received 200 mg of itraconazole per day, and the control group received 10 mg of prednisolone per day, for 32 weeks, in addition to the classic treatment of asthma. The subjects were randomly divided into two groups, and assigned by sealed envelope. Blinding was performed by repacking the drug in a similar container. Primary outcomes were asthma control test score, fibroblast growth factor 2, and wall area percentage on RB1 bronchus measured by computed tomography. The outcomes were compared in subjects classified as allergic, eosinophilic, T2 low asthma, and four types of inflammatory cell classification in sputum.</p><p><strong>Results: </strong>Seventy subjects finished the 32-week trial (35 subjects in each group). Baseline data did not show significant differences between groups. A comparison of asthma variants showed significantly more severe cough and dyspnea in the allergic variant and higher spirometry results in T2-low asthma. Sputum cytology revealed a mixed pattern as the most frequent type (47%). After the trial, two groups improved in many parameters; however, FGF-2 improved more significantly by itraconazole (4.66±16.92 decreased to 1.14±2.98), and FEV1/FVC was significantly higher in the itraconazole group, compared to the control group. These results did not change in terms of asthma variants and sputum classification.</p><p><strong>Conclusion: </strong>Itraconazole was superior to prednisolone in the treatment of many clinical and spirometry aspects in severe persistent asthma.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular epidemiology of clinically relevant single and mixed species in a Malaysian tertiary care hospital.","authors":"Humaira Farooq, Gokul Shankar Sabesan, Tahmina Monowar, Suresh V Chinni, Noor Hasliza Zainol, SweSwe Latt, Rajesh Pk","doi":"10.18502/cmm.2023.345062.1432","DOIUrl":"10.18502/cmm.2023.345062.1432","url":null,"abstract":"<p><strong>Background and purpose: </strong>The increasing rate of opportunistic infections caused by <i>Candida</i> and other yeasts is becoming a major health concern worldwide. However, systematic data on the epidemiology and the yeast species infections in Malaysia is still limited. In this regard, the present research aimed to identify pathogenic yeasts utilizing an economically practical and easily available molecular technique and evaluate the prevalence of pathogenic yeasts in a Malaysian tertiary care hospital.</p><p><strong>Materials and methods: </strong>Yeast isolates were collected from Sultan Abdul Halim Hospital, Kedah, Malaysia, from October 2020 to October 2021. Molecular identification of the isolates was performed by one enzyme-based polymerase chain reaction-restriction fragment length polymorphism method.</p><p><strong>Results: </strong><i>Candida albicans</i> was the most prevalent species, accounting for 120 isolates (59%) in total. The most prevalent non-<i>albicans Candida</i> species were <i>C. tropicalis</i> (n=33, 16%), <i>C. krusei</i> (Pichia kudriavzevii) (n=12, 5.8%), <i>C. glabrata</i> (n=12, 5.8%), and <i>C. parapsilosis</i> (n=6, 3%). Other unusual <i>Candida</i> species were <i>C. guilliermondii</i> (2), <i>C. metapsilosis</i> (2), <i>C. orthopsilosis</i> (1), <i>C. lusitaniae</i> (1), <i>C. rugosa</i> (1), <i>C. haemulonii</i> (1), <i>C. bracarensis</i> (1), and <i>C. dubliniensis</i> (1). Moreover, <i>Talaromyces marneffei</i> (1), <i>Kodamaea ohmeri</i> (1), <i>Cryptococcus neoformans</i> (3), and <i>Cryptococcus laurentii</i> (1) were among the other yeasts identified.</p><p><strong>Conclusion: </strong>The Molecular technique used in this study identified 96% of isolates, including mixed species. According to the findings, the most prevalent species are <i>C. albicans</i>, <i>C. tropicalis</i>, <i>C. krusei</i>, and <i>C. glabrata</i>.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"23-28"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D₃: A promising antifungal and antibiofilm agent against <i>Candida</i> species.","authors":"Zahra Kherad, Somayeh Yazdanpanah, Farshid Saadat, Keyvan Pakshir, Kamiar Zomorodian","doi":"10.18502/cmm.2023.345062.1416","DOIUrl":"10.18502/cmm.2023.345062.1416","url":null,"abstract":"<p><strong>Background and purpose: </strong><i>Candida</i> species are opportunistic fungal pathogens that cause mild to life-threatening infections in both immunocompetent and immunocompromised populations. The increasing prevalence of drug-resistant <i>Candida</i> species has posed a significant challenge to the management of infections in clinical settings. Therefore, this study aimed to investigate the direct antifungal and antibiofilm effect of vitamin D₃ against <i>Candida</i> species.</p><p><strong>Materials and methods: </strong>The antifungal activity of vitamin D₃ was evaluated by broth microdilution method based on the Clinical and Laboratory Standard Institute. Prevention of biofilm formation by <i>Candida albicans</i> was measured using the XTT assay following exposure to different concentrations of vitamin D₃. Moreover, expression of <i>Agglutinin-like sequence</i> gene 1 (<i>ALS</i>1), <i>hyphal wall protein</i> gene (<i>HWP</i>1), <i>secreted aspartyl proteinase</i> 6 gene (<i>SAP</i>6), and <i>morphogenesis pathway regulatory</i> gene (<i>EFG</i>1) were analyzed by real-time polymerase chain reaction using the comparative Ct method (ΔΔ Ct) after exposure to vitamin D₃.</p><p><strong>Results: </strong>Vitamin D₃ showed antifungal activity against <i>Candida</i> species ranging from 1-128 μg/mL. Furthermore, vitamin D₃ inhibited biofilm formation in a dose-dependent manner, with IC50 of 7.5 μg/mL. Treatment with vitamin D₃ resulted in significant upregulation of the <i>EFG</i>1, <i>ALS</i>1, and <i>SAP</i>6 genes under hypha-inducing conditions to overcome environmental challenges.</p><p><strong>Conclusion: </strong>Results of the current study demonstrated that vitamin D₃ has a significant inhibitory effect on <i>Candida</i> growth and biofilm formation. Considering its demonstrated antifungal and antibiofilm properties, vitamin D₃ holds promise as a potential agent for medical applications.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"17-22"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of acidifying agents and clotrimazole for treatment of otomycosis: a comprehensive one-way mini-review.","authors":"Zeynab Yassin, Behrooz Amirzargar, Reza Ghasemi, Farnaz Valizadeh, Mahsa Fattahi","doi":"10.18502/cmm.2023.345035.1402","DOIUrl":"10.18502/cmm.2023.345035.1402","url":null,"abstract":"<p><strong>Background and purpose: </strong>This review aimed to compare the efficacy of acidifying agents and clotrimazole in the treatment of patients with otomycosis.</p><p><strong>Materials and methods: </strong>The databases, including Research Gate, Google Scholar, ScienceDirect, Embase, Medline, Scopus, Cochrane, and library databases of clinical trials were searched in this study. The keywords were \"Fungal Ear Infection\" and \"Otitis External\" for otomycosis, \"Clotrimazole\", Lotrimin\", \"Mycelex\", \"Desenex\", and \"Clotrimaderm Mycoderm\" for clotrimazole, and \"Boric Acid Alcohol\", \"Alcohol-vinegar solution\", Burow solution (Domeboro), \"Isopropyl Alcohol\", \"VoSol\" and \"Acetic Acid\" for acidifying agents. Regarding search strategy, a total of 53 studies were collected, 11 of which were maintained for assessment. Almost all studies were published after 1990. These articles discussed the role of clotrimazole and acidifying compounds in the treatment of otomycosis. Moreover, the route of administration, dosage, and side effects of these medications were highlighted.</p><p><strong>Results: </strong>Eight studies had similar results and claimed that clotrimazole has the best or most significant effect on the treatment of otomycosis for patients suffering from pain, itching, swelling, and hearing loss.</p><p><strong>Conclusion: </strong>Although all medications appear effective, there is a paucity of evidence to fully support the decision to choose between clotrimazole or acidifying agents for the treatment of otomycosis in terms of both efficacy and safety. However, in the biomedical field, the re-emerging investigation attention is due to the statements of a number of mechanisms defending the use of acidifying agents to treat mycosis (of antifungal-resistant species).</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"45-51"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular identification and antifungal susceptibility profiles of etiologic agents of oral candidiasis among HIV-positive patients: A multicenter study.","authors":"Hamid Morovati, Malihe Jokari, Saba Eslami, Kamiar Zomorodian, Katayoun Taeri, Nesa Khalaf, Hossein Khodadadi","doi":"10.18502/CMM.2023.345058.1414","DOIUrl":"10.18502/CMM.2023.345058.1414","url":null,"abstract":"<p><strong>Background and purpose: </strong>Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) is a serious risk factor for oral candidiasis (OC). In this regard, the present study aimed to investigate the frequency of <i>Candida</i> species collected from the oropharyngeal cavity of HIV-positive patients and the sensitivity of these isolates to antifungal drugs.</p><p><strong>Materials and methods: </strong>Oral samples were collected from 169 HIV-positive patients. In addition to culture-based methods, a molecular assay via the polymerase chain reaction-restriction fragment length polymorphism method was applied to identify isolates using the <i>MspI</i> restriction enzyme. The disk diffusion method determined the susceptibility of isolated yeasts to common antifungal drugs according to the CLSI M44-A2 protocol.</p><p><strong>Results: </strong>In total, 81 participants (47.92%) were positive for OC, and <i>Candida albicans</i> was the most prevalent yeast (53.98%). The median age of patients was 36 years old (IQR=10.5; 17-59), and it was found that women are 27% more susceptible to HIV-associated OC (OR=1.268; 95% CI: 0.685-2.348). Patients who received antifungal therapy had a 97.3% reduced chance for OC (OR: 0.027; 95% CI: 0.008-0.091; <i>P-value</i>: 0.000). Antifungal therapy reduced the risk of OC by 97.3% (OR=0.027; 95% CI=0.008-0.091; <i>P</i>=0.000), and antiretroviral therapy decreased the chance of OC 4.42 times (OR=4.423; 95% CI=1.697-11.528; <i>P</i>=0.002). The resistance rates for antifungals, namely fluconazole, ketoconazole, itraconazole, amphotericin B, and nystatin were 15.93%, 8.85%, 7.96%, 5.31%, and 4.42%, respectively.</p><p><strong>Conclusion: </strong>Although several decades have passed since the emergence of HIV/AIDS, little information is available about fungal colonization and infections in this population. Further investigations are suggested using novel and reference molecular identification methods, such as matrix-assisted laser desorption ionization time-of-flight mass spectrometry and sequencing, respectively. In addition, more reliable methods for antifungal susceptibility testing are recommended.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"10-16"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates on Tinea Incognita: Literature review.","authors":"Aliasghar Ghaderi, Pegah Tamimi, Alireza Firooz, Maryam Fattahi, Mona Ghazanfari, Mahsa Fattahi","doi":"10.22034/cmm.2023.345069.1425","DOIUrl":"10.22034/cmm.2023.345069.1425","url":null,"abstract":"<p><strong>Background and purpose: </strong>Tinea incognita (TI), or the other equivalent tinea atypica, is a term used to declare the atypical presentation of dermatophyte infections caused by the administration of steroids or other immunosuppressive medications which modulate the local and systemic immune response. It can mimic other dermatoses; hence making diagnostic challenges for dermatologists. Tina incognita may be misdiagnosed as many dermatoses. Based on previous studies, corticosteroids may cause different clinical manifestations of dermatophytes that might be very different from those that are commonly described.</p><p><strong>Materials and methods: </strong>This narrative review was conducted using PubMed and Scopus databases. Search terms included \"Tinea incognita\" and \"Atypical dermatophytosis\". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, reviews, and case reports. The search was restricted to articles written in the English language from 2006 to Feb 01, 2023. Moreover, duplicate articles and non-available full-text articles were excluded. The extracted data of the search results were retrieved in this study. The morphological patterns, prevalence, sight of infection, and causative agents were also described.</p><p><strong>Results: </strong>Prevalence of different patterns of TI were recorded as 50% (431 out of 862 cases) for eczema-like lesions followed by psoriasis-like and 6.61% (57 out of 862) for parapsoriasis-like pattern. Moreover, each of the rosacea-like and pyoderma-like lesions equally accounted for 4.98 % of cases (43 out of 862). In addition, the prevalence of causative agents was reported as follows: <i>Trichophyton rubrum</i> accounted for 247 isolates (40%) as the most prevalent, followed by <i>Trichophyton mentagrophytes</i> (n=152, 24%) and <i>Microsporum canis</i> (n=119, 19%).</p><p><strong>Conclusion: </strong>Tinea incognita is a great mimicker; hence, dermatologists should obtain a full medical history of the patients to make correct diagnoses. It is vital to encourage an exact identification of the etiological agent according to the internal transcribed spacer sequencing in some uncertain cases. This review highlights the importance of mycological tests and fast diagnosis of TI, especially in cases of atypical skin lesions, to choose appropriate treatment and avoid the spread of drug-resistant species.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"52-63"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antifungal activity of Allyl isothiocyanate by targeting signal transduction pathway, ergosterol biosynthesis, and cell cycle in <i>Candida albicans</i>.","authors":"Shivani Balasaheb Patil, Ashwini Khanderao Jadhav, Rakesh Kumar Sharma, Sargun Tushar Basrani, Tanjila Chandsaheb Gavandi, Sayali Ashok Chougule, Shivanand Ramappa Yankanchi, Sankunny Mohan Karuppayil","doi":"10.22034/CMM.2023.345081.1429","DOIUrl":"10.22034/CMM.2023.345081.1429","url":null,"abstract":"<p><strong>Background and purpose: </strong>In recent years, the inclusion of <i>Candida albicans</i> on the list of infections that pose a threat due to drug resistance has urged researchers to look into cutting-edge and effective antifungal medications. In this regard, the current study investigated the probable mode of action of allyl isothiocyanate (AITC) against <i>Candida albicans</i>.</p><p><strong>Materials and methods: </strong>In this study, planktonic assay, germ tube inhibition assay, adhesion, and biofilm formation assay were performed to check the growth and virulence factors. Furthermore, ergosterol assay, reactive oxygen production analysis, cell cycle analysis, and quantitative real-time polymerase chain reaction analysis were performed with the aim of finding the mode of action. A biomedical model organism, like a silkworm, was used in an <i>in vivo</i> study to demonstrate AITC anti-infective ability against <i>C. albicans</i> infection.</p><p><strong>Results: </strong>Allyl isothiocyanate completely inhibited ergosterol biosynthesis in <i>C. albicans</i> at 0.125 mg/ml. Allyl isothiocyanate produces reactive oxygen species in both planktonic and biofilm cells of <i>C. albicans</i>. At 0.125 mg/ml concentration, AITC arrested cells at the G2/M phase of the cell cycle, which may induce apoptosis in <i>C. albicans</i>. In quantitative real-time polymerase chain reaction analysis, it was found that AITC inhibited virulence factors, like germ tube formation, at 0.125 mg/ml concentration by downregulation of <i>PDE2</i>, <i>CEK1</i>, <i>TEC1</i> by 2.54-, 1.91-, and 1.04-fold change, respectively, and upregulation of <i>MIG1</i>, <i>NRG1</i>, and <i>TUP1</i> by 9.22-, 3.35-, and 7.80-fold change, respectively. The <i>in vivo</i> study showed that AITC treatment successfully protected silkworms against <i>C. albicans</i> infections and increased their survival rate by preventing internal colonization by <i>C. albicans</i>.</p><p><strong>Conclusion: </strong><i>In vitro</i> and <i>in vivo</i> studies revealed that AITC can be an alternative therapeutic option for the treatment of <i>C. albicans</i> infection.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"29-38"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of onychomycosis on the quality of life of patients.","authors":"Fayrouz Debbagh, Fatima Babokh, Mohamed Sbai, El Mostafa El Mezouari, Redouane Moutaj","doi":"10.18502/cmm.2023.345062.1430","DOIUrl":"10.18502/cmm.2023.345062.1430","url":null,"abstract":"<p><strong>Background and purpose: </strong>Onychomycosis is a very common cosmopolitan onychopathy. It affects the fingers and toes, which are important organs of function and socialization. They can cause physical and psychological discomfort. In this regard, the present study aimed to assess the impact of onychomycosis on the quality of life of patients.</p><p><strong>Materials and methods: </strong>This prospective, cross-sectional, observational study was carried out in the parasitology-mycology laboratory of the Avicenne Military Hospital in Marrakesh, Morocco, over 5 months between June and October 2022. The study population was all the patients referred to the laboratory for mycological examination of a nail lesion suspected of onychomycosis of the hands and/or feet.</p><p><strong>Results: </strong>Onychomycosis was confirmed in 50 patients. Pain, nail thickening, and dyschromia were the most commonly reported symptoms (56%). Onychomycosis had an impact on at least one of the socio-economic, emotional, or functional aspects of the lives of affected patients. More than half (56%) of participants felt embarrassed by the appearance of their nails, 40% hid them, and 28% had a complex about them. The functional aspect was the most bothersome and the time spent on nail care concerned the patients (56%), as well as the discomfort reported when wearing shoes (40%). Women were more worried about the need to hide their nails. A duration of onychomycosis evolution of over 5 years was associated with the highest response rate to the questionnaire (66%).</p><p><strong>Conclusion: </strong>Although onychomycosis is not a fatal pathology, it significantly reduces the quality of life of affected patients. There is a need to raise the level of awareness of the general population and, above all, of the medical professionals to ensure comprehensive management of onychomycosis.</p>","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 2","pages":"39-44"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}